Tuberculosis subunit vaccines: from basic science to clinical testing

Bibliography

• FARHAT M, GREENAWAY C, PAI M, MENZIES D: False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int. J. Tuberc. Lung Dis. (2006) 10(11):1192-1204.
   PubMed Web of Science ®Google Scholar
• FINE PE: Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 346:1339-1345.
   Google Scholar
• AL-KASSIMI FA, AL-HAJJAJ MS, AL-ORAINEY IO, EA B: Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am. J. Respir. Crit. Care Med. (1995) 152(5):1575-1578.
   PubMed Web of Science ®Google Scholar
• COLDITZ GA, BERKEY CS, MOSTELLER F et al.: The efficacy of bacillus Calmette–GuÉrin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics (1995) 96(1 Part 1):29-35.
   PubMed Web of Science ®Google Scholar
• COLDITZ GA, BREWER TF, BERKEY CS et al.: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA (1994) 271(9):698-702.
   PubMed Web of Science ®Google Scholar
• LANCKRIET C, LEVY BD, BINGONO E, SIOPATHIS RM, GUERIN N: Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui. Int. J. Epidemiol. (1995) 24(5):1042-1049.
   PubMed Web of Science ®Google Scholar
• STERNE JA, RODRIGUES LC, GUEDES IN: Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung Dis. (1998) 2(3):200-207.
   PubMed Web of Science ®Google Scholar
• ARONSON NE, SANTOSHAM M, COMSTOCK GW et al.: Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA (2004) 291(17):2086-2091.
   PubMed Web of Science ®Google Scholar
• COMSTOCK GW, WOOLPERT SF, LIVESAY VT: Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep. (1976) 91(3):276-280.
   PubMed Web of Science ®Google Scholar
• HART PD, SUTHERLAND I: BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J. (1977) 2(6082):293-295.
   PubMed Web of Science ®Google Scholar
• ANON: Global Tuberculosis Control. WHO Report 2002. (WHO/CDS/TB/2001.287). World Health Organization (2002).
   Google Scholar
• BASARABA RJ, IZZO AA, BRANDT L, ORME IM: Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine (2006) 24(3):280-286.
   PubMed Web of Science ®Google Scholar
• BRANDT L, FEINO CUNHA J, WEINREICH OLSEN A et al.: Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. (2002) 70(2):672-678.
   PubMed Web of Science ®Google Scholar
• BUDDLE BM, WARDS BJ, ALDWELL FE, COLLINS DM, DE LISLE GW: Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine (2002) 20(7-8):1126-1133.
   PubMed Web of Science ®Google Scholar
• DOHERTY TM, ANDERSEN P: Tuberculosis vaccine development. Curr. Opin. Pulm. Med. (2002) 8(3):183-187.
   PubMed Web of Science ®Google Scholar
• ROTH A, GARLY ML, JENSEN H, NIELSEN J, AABY P: Bacillus Calmette–GuÉrin vaccination and infant mortality. Expert Rev. Vaccines (2006) 5(2):277-293.
   PubMed Web of Science ®Google Scholar
• TRUNZ BB, FINE P, DYE C: Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet (2006) 367(9517):1173-1180.
   PubMed Web of Science ®Google Scholar
• ORME IM: Beyond BCG: the potential for a more effective TB vaccine. Mol. Med. Today (1999) 5(11):487-492.
   PubMedGoogle Scholar
• SMITH DA, PARISH T, STOKER NG, BANCROFT GJ: Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Immun. (2001) 69(2):1142-1150.
   PubMed Web of Science ®Google Scholar
• WILLIAMS A, HATCH GJ, CLARK SO et al.: Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb.) (2005) 85(1-2):29-38.
   PubMed Web of Science ®Google Scholar
• SNIDER DE Jr: Ethical issues in tuberculosis vaccine trials. Clin. Infect. Dis. (2000) 30(Suppl. 3):S271-S275.
   PubMedGoogle Scholar
• HORWITZ MA, HARTH G, DILLON BJ, MASLESA-GALIC S: A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine (2006) 24(10):1593-1600.
   PubMed Web of Science ®Google Scholar
• CONRADT P, HESS J, KAUFMANN SH: Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin. Microbes. Infect. (1999) 1(10):753-764.
   PubMed Web of Science ®Google Scholar
• GRODE L, KURSAR M, FENSTERLE J, KAUFMANN SH, HESS J: Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette–GuÉrin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J. Immunol. (2002) 168(4):1869-1876.
   PubMed Web of Science ®Google Scholar
• HORWITZ MA, HARTH G: A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. (2003) 71(4):1672-1679.
   PubMed Web of Science ®Google Scholar
• WINAU F, WEBER S, SAD S et al.: Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity (2006) 24(1):105-117.
   PubMed Web of Science ®Google Scholar
• DIETRICH J, BILLESKOV R, DOHERTY TM, ANDERSEN P: Synergistic effect of bacillus Calmette–GuÉrin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J. Immunol. (2007) 178(6):3721-3730.
   PubMed Web of Science ®Google Scholar
• ANDERSEN P: The T cell response to secreted antigens of Mycobacterium tuberculosis. Immunobiology (1994) 191(4-5):537-547.
   PubMed Web of Science ®Google Scholar
• ANDERSEN P, ASKGAARD D, LJUNGQVIST L, BENTZON MW, HERON I: T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect. Immun. (1991) 59(4):1558-1563.
   PubMed Web of Science ®Google Scholar
• DIETRICH J, WELDINGH K, ANDERSEN P: Prospects for a novel vaccine against tuberculosis. Vet. Microbiol. (2006) 112(2-4):163-169.
   PubMed Web of Science ®Google Scholar
• DOHERTY TM, OLSEN AW, WEISCHENFELDT J et al.: Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J. Infect. Dis. (2004) 190(12):2146-2153.
   PubMed Web of Science ®Google Scholar
• SKEIKY YA, ALDERSON MR, OVENDALE PJ et al.: Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. (2004) 172(12):7618-7628.
   PubMed Web of Science ®Google Scholar
• DREXLER I, STAIB C, SUTTER G: Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr. Opin. Biotechnol. (2004) 15:506-512.
   PubMed Web of Science ®Google Scholar
• WANG J, THORSON L, STOKES RW et al.: Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. (2004) 173(10):6357-6365.
   PubMed Web of Science ®Google Scholar
• GOONETILLEKE NP, MCSHANE H, HANNAN CM et al.: Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette–GuÉrin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. (2003) 171(3):1602-1609.
   PubMed Web of Science ®Google Scholar
• MCSHANE H, PATHAN AA, SANDER CR et al.: Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. (2004) 10(11):1240-1244.
   PubMed Web of Science ®Google Scholar
• SANDER C, MCSHANE H: Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis. Clin. Exp. Immunol. (2007) 147(3):401-411.
   PubMed Web of Science ®Google Scholar
• VOGELS R, ZUIJDGEEST D, VAN RIJNSOEVER R et al.: Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. (2003) 77(15):8263-8271.
   PubMed Web of Science ®Google Scholar
• RADOSEVIC K, WIELAND CW, RODRIGUEZ A et al.: Protective immune responses to an rAd35 TB vaccine in two mouse strains (H-2d vs. H-2b): CD4 and CD8 T-cell epitope mapping and role of IFN{Γ}. Infect. Immun. (2007).
   PubMedGoogle Scholar
• ROONEY JF, WOHLENBERG C, CREMER KJ, MOSS B, NOTKINS AL: Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J. Virol. (1988) 62(5):1530-1534.
   PubMed Web of Science ®Google Scholar
• DOHERTY TM, OLSEN AW, VAN PINXTEREN L, ANDERSEN P: Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun. (2002) 70(6):3111-3121.
   PubMed Web of Science ®Google Scholar
• HOGARTH PJ, JAHANS KJ, HECKER R, HEWINSON RG, CHAMBERS MA: Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs. Vaccine (2003) 21(9-10):977-982.
   PubMed Web of Science ®Google Scholar
• HOLTEN-ANDERSEN L, DOHERTY TM, KORSHOLM KS, ANDERSEN P: Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. (2004) 72(3):1608-1617.
   PubMed Web of Science ®Google Scholar
• LINGNAU K, EGYED A, SCHELLACK C et al.: Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine (2002) 20(29-30):3498-3508.
   PubMed Web of Science ®Google Scholar
• PEPPOLONI S, RUGGIERO P, CONTORNI M et al.: Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines (2003) 2(2):285-293.
   PubMedGoogle Scholar
• ULRICH JT, MYERS KR: Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. (1995) 6:495-524.
   PubMedGoogle Scholar
• KOCH R: Classics in infectious diseases. The etiology of tuberculosis: Robert Koch. Berlin, Germany 1882. Rev. Infect. Dis. (1982) 4(6):1270-1274.
   PubMedGoogle Scholar
• ROOK GA, STANFORD JL: The Koch phenomenon and the immunopathology of tuberculosis. Curr. Top. Microbiol. Immunol. (1996) 215:239-262.
   PubMed Web of Science ®Google Scholar
• GILBERT SC, MOORTHY VS, ANDREWS L et al.: Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine (2006) 24(21):4554-4561.
   PubMed Web of Science ®Google Scholar
• ANON: Global Tuberculosis Control – Surveillance, Planning, Financing. (WHO/HTM/TB/2005). World Health Organization (2005).
   Google Scholar
• BAILY GV: Tuberculosis prevention Trial, Madras. Indian J. Med. Res. (1980) 72:1-74.
   PubMed Web of Science ®Google Scholar
• MULHOLLAND K: Evaluation of vaccines to prevent childhood pneumonia: lessons relevant to planning tuberculosis vaccine trials. Clin. Infect. Dis. (2000) 30(Suppl. 3):S206-S209.
   PubMed Web of Science ®Google Scholar
• LALVANI A, BAKIR M, MILLINGTON KA, DOSANJH D, SOYSAL A: BCG and protection against Mycobacterium tuberculosis infection. Lancet (2006) 367(9508):391-392.
   PubMed Web of Science ®Google Scholar
• SOYSAL A, MILLINGTON KA, BAKIR M et al.: Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet (2005) 366(9495):1443-1451.
   PubMed Web of Science ®Google Scholar
• LYASHCHENKO K, WHELAN AO, GREENWALD R et al.: Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with Mycobacterium bovis BCG and infected with M. bovis. Infect. Immun. (2004) 72(5):2462-2467.
   PubMed Web of Science ®Google Scholar
• VORDERMEIER HM, CHAMBERS MA, COCKLE PJ et al.: Correlation of ESAT-6-specific Γ interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun. (2002) 70(6):3026-3032.
   PubMed Web of Science ®Google Scholar
• DOHERTY TM, DEMISSIE A, OLOBO J et al.: Immune responses to the Mycobacterium tuberculosis – specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. (2002) 40(2):704-706.
   PubMed Web of Science ®Google Scholar
• ANDERSEN P, DOHERTY TM, PAI M, WELDINGH K: The prognosis of latent tuberculosis: can disease be predicted? Trends Mol. Med. (2007) 13(5):175-182.
   PubMed Web of Science ®Google Scholar
• TURNER J, RHOADES ER, KEEN M et al.: Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect. Immun. (2000) 68(3):1706-1709.
   PubMed Web of Science ®Google Scholar
• TURNER OC, ROBERTS AD, FRANK AA et al.: Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis. Infect. Immun. (2000) 68(6):3674-3679.
   PubMed Web of Science ®Google Scholar
• ZIV E, DALEY CL, BLOWER S: Potential public health impact of new tuberculosis vaccines. Emerg. Infect. Dis. (2004) 10(9):1529-1535.
   PubMed Web of Science ®Google Scholar
• ANDERSEN P: Vaccine strategies against latent tuberculosis infection. Trends Microbiol. (2007) 15(1):7-13.
   PubMed Web of Science ®Google Scholar
• LANGERMANS JA, DOHERTY TM, VERVENNE RA et al.: Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine (2005) 23(21):2740-2750.
   PubMed Web of Science ®Google Scholar
• DHILLON J, MITCHISON DA: Effect of vaccines in a murine model of dormant tuberculosis. Tuber. Lung Dis. (1994) 75(1):61-64.
   PubMedGoogle Scholar
• REPIQUE CJ, LI A, COLLINS FM, MORRIS SL: DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect. Immun. (2002) 70(7):3318-3323.
   PubMed Web of Science ®Google Scholar
• TAYLOR JL, TURNER OC, BASARABA RJ et al.: Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. (2003) 71(4):2192-2198.
   PubMed Web of Science ®Google Scholar
• LOWRIE DB, TASCON RE, BONATO VL et al.: Therapy of tuberculosis in mice by DNA vaccination. Nature (1999) 400(6741):269-271.
   PubMed Web of Science ®Google Scholar
• DEMISSIE A, LEYTEN EM, ABEBE M et al.: Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin. Vaccine Immunol. (2006) 13(2):179-186.
   PubMed Web of Science ®Google Scholar
• LIN MY, GELUK A, SMITH SG et al.: Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. Infect. Immun. (2007) 75(7):3523-3530.
   PubMed Web of Science ®Google Scholar
• GOMEZ-REINO JJ, CARMONA L, ANGEL DESCALZO M: Risk of tuberculosis in patients treated with TNF antagonists due to incomplete prevention of reactivation of latent infection. Arthritis. Rheum. (2007) 57(5):756-761.
   PubMed Web of Science ®Google Scholar
• IBANGA HB, BROOKES RH, HILL PC et al.: Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis – endemic countries: issues in study design. Lancet Infect. Dis. (2006) 6(8):522-528.
   PubMed Web of Science ®Google Scholar
• MCSHANE H, BROOKES R, GILBERT SC, HILL AV: Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. (2001) 69(2):681-686.
   PubMed Web of Science ®Google Scholar
• HAVENGA M, VOGELS R, ZUIJDGEEST D et al.: Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J. Gen. Virol. (2006) 87(Part 8):2135-2143.
   PubMed Web of Science ®Google Scholar
• AGGER EM, ROSENKRANDS I, OLSEN AW et al.: Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine (2006) 24(26):5452-5460.
   PubMed Web of Science ®Google Scholar
• DIETRICH J, ANDERSEN C, RAPPUOLI R et al.: Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette–GuÉrin immunity. J. Immunol. (2006) 177(9):6353-6360.
   PubMed Web of Science ®Google Scholar
• TSENOVA L, HARBACHEUSKI R, MOREIRA AL et al.: Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect. Immun. (2006) 74(4):2392-2401.
   PubMed Web of Science ®Google Scholar
• BRANDT L, SKEIKY YA, ALDERSON MR et al.: The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. (2004) 72(11):6622-6632.
   PubMed Web of Science ®Google Scholar